Before the recent recall, cough drops were widely regarded as a reliable remedy for soothing sore throats and alleviating cough symptoms. Consumers had high expectations for the safety and efficacy of these products, particularly those manufactured by reputable companies like Xiamen Kang Zhongyuan Biotechnology Co., Ltd. However, a significant shift occurred following an FDA inspection that raised concerns about the quality of these cough suppressants.
On April 13, 2026, Xiamen Kang Zhongyuan Biotechnology Co. voluntarily announced a recall of cough suppressants sold nationwide. This recall covered 15 varieties of cough drops marketed under various name brands, including Exchange Select, Caring Mill, Discount Drug, MGC Health, and QC Quality Choice. The decision to initiate the recall was prompted by an FDA inspection conducted on August 15, 2025, which revealed observations affecting product quality.
The FDA classified this recall as Class II, indicating that the products could potentially cause temporary or medically reversible health consequences. The recall was officially issued on March 20, 2026, and affected products included popular flavors such as Honey Lemon, Cherry, and Menthol. The expiration dates of the recalled products ranged from May 24, 2026, to October 30, 2026, raising concerns among consumers regarding the safety of these cough drops.
While the FDA did not specify the total number of items included in the recall, it did highlight specific counts for some affected products. For instance, there were 30 units of Exchange Select Honey Lemon Cough Drops, 90 units of Caring Mill Cherry Cough Drops, and 25 units of QC Quality Choice Sugar-Free Black Cherry Cough Drops. Such figures illustrate the scale of the recall and its potential impact on consumers.
The immediate effects of the recall were felt by both consumers and retailers. Many consumers were left uncertain about the safety of the cough drops they had purchased, leading to increased anxiety and confusion. Retailers, on the other hand, faced the challenge of managing the recall process, including removing the affected products from their shelves and informing customers about the situation.
Experts in public health and consumer safety have emphasized the importance of such recalls in maintaining product integrity and consumer trust. The FDA’s proactive approach in inspecting manufacturing facilities and addressing quality concerns is seen as a crucial step in safeguarding public health. As noted by industry analysts, recalls like this one serve as a reminder of the need for stringent quality control measures in the production of over-the-counter medications.
As the situation continues to develop, consumers are advised to check their medicine cabinets for any affected cough drops and to follow the recall instructions provided by the company. Details remain unconfirmed regarding the exact number of products affected, but the implications of this recall are significant for both the manufacturer and the public.
